Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 22, 2006. The report discloses the granting of awards and options to senior executives, including Executive Directors and Persons Discharging Managerial Responsibility (PDMRs), under the GlaxoSmithKline Performance Share Plan and the GlaxoSmithKline Share Option Plan. The grants were made on February 21, 2006, in compliance with UK Listing and Disclosure Rules following the Market Abuse Directive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and grant details.
Material Changes and Grant Details
On February 21, 2006, the Company granted new equity awards subject to performance conditions. Dr. Yamada was excluded from these grants due to his scheduled retirement on June 1, 2006.
- Performance Share Plan:
- Measurement Period: January 1, 2006, to December 31, 2008.
- Condition: Total Shareholder Return (TSR) relative to 13 comparator companies.
- Vesting Thresholds: No vesting if TSR ranks below 7th position. Sliding scale applies up to 100% vesting for 1st or 2nd position.
- Maximum Potential Awards (Ordinary Shares): Ranges from 17,500 (Mrs. J. Younger) to 100,000 (Mr. J.S. Heslop).
- Maximum Potential Awards (ADSs): Ranges from 25,000 (Dr. F. Calhoun, Dr. R. Greig, Dr. D. Pulman) to 220,000 (Dr. J.P. Garnier).
- Share Option Plan:
- Subscription Price: GBP 14.68 per Ordinary Share (US$51.02 per ADS).
- Performance Period: January 1, 2006, to December 31, 2008.
- Condition: Compound annual increase in Earnings Per Share (EPS) versus Retail Prices Index (RPI).
- Vesting Thresholds: No vesting unless EPS growth exceeds RPI by 3% p.a. 50% vests at 3% excess; 100% vests at 6% excess or more.
- Maximum Potential Options (Ordinary Shares): Ranges from 41,000 (Mrs. J. Younger) to 231,000 (Mr. J.S. Heslop).
- Maximum Potential Options (ADSs): Ranges from 57,500 (Dr. F. Calhoun, Dr. R. Greig, Dr. D. Pulman) to 500,000 (Dr. J.P. Garnier).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding operational performance. The primary risk disclosed relates to the performance conditions of the equity awards; if the Company fails to meet the specified TSR or EPS growth targets relative to the comparator group or RPI, the awards will not vest or will vest at reduced levels.
Investor Verification Checklist
- Verify the specific list of 13 comparator companies used for the TSR performance condition.
- Confirm the exact calculation methodology for the sliding scale vesting between the 2nd and 7th positions.
- Monitor the Company's EPS growth trajectory against the Retail Prices Index (RPI) to assess option vesting probability.
- Review the impact of Dr. Yamada's retirement on the overall executive compensation structure.
- Check subsequent filings for actual vesting outcomes based on the 2006-2008 performance period.